Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs
Amedeo Capetti(Luigi Sacco Hospital), Giuliano Rizzardini, Simona Landonio(ASST Fatebenefratelli Sacco), Gianfranco Dedivitiis(Luigi Sacco Hospital), Stefania Vimercati(Qinetiq (United Kingdom)), Laura Carenzi(Luigi Sacco Hospital), Mariangela Micale(Qinetiq (United Kingdom)), Fosca Niero(Luigi Sacco Hospital)
Cited by 3
Related Papers
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|97